共 254 条
- [1] Dhamoon MS(2006)Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study Neurology 66 641-646
- [2] Sciacca RR(2020)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J 41 111-188
- [3] Rundek T(2012)Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study Circulation 125 1979-1987
- [4] Sacco RL(2019)Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNa guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines J Am Coll Cardiol 73 3210-3227
- [5] Elkind MS(2018)Role of PCSK9 in lipid metabolism and atherosclerosis Biomed Pharmacother 104 36-44
- [6] Mach F(2012)Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways Transl Res 160 125-130
- [7] Baigent C(2021)Proprotein convertase subtilisin/kexin type 9: a view beyond the canonical cholesterol-lowering impact Am J Pathol 191 1385-1397
- [8] Catapano AL(2008)Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration Hepatology 48 646-654
- [9] Koskinas KC(2021)Lipid-lowering therapy and hemorrhagic stroke risk: comparative meta-analysis of statins and PCSK9 inhibitors Stroke 52 3142-3150
- [10] Casula M(2015)Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk Circulation 132 1648-1666